Clinical trials: Docetaxel, completed
Ovarian Cancer, Fallopian Tube Cancer
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT03740165
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 227 sites in United States, Australia and 20 more
- Volunteers
- 1,367 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003037
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine followed by docetaxel in treating patients…
- Trial name
- NCT00026156
- Testing
- docetaxel, vinorelbine tartrate
- Where
- 96 sites in United States
- Volunteers
- 125 people
- Sponsor
- SWOG Cancer Research Network
Head and Neck Squamous Cell Carcinoma
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
The primary objective of this clinical study is to compare the pharmacokinetic parameters of drugs RPH-002 and Erbitux® after a single intravenous administration, as well as to evaluate the safety of drug RPH-002 in comparison…
- Trial name
- NCT07435311
- Testing
- RPH-002, Erbitux®, cisplatin
- Where
- 18 sites in Russia
- Volunteers
- 118 people
- Sponsor
- R-Pharm
Pulmonary Neoplasms
Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the safety and efficacy of the preoperative docetaxel and docetaxel-cisplatin combination in c-stage IB/II NSCLC, and select the optimal preoperative therapy for phase III trials.
- Trial name
- NCT00132639
- Testing
- Preoperative docetaxel-cisplatin combination chemotherapy, Preoperative docetaxel monotherapy
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Haruhiko Fukuda
Non-Small Cell Lung Cancer
BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC
Lung cancer is the leading cause of cancer death in Korea as well as in other countries. About 80% of lung cancer is non-small cell lung cancer(NSCLC).
- Trial name
- BELOXAN (NCT01243775)
- Testing
- Belotaxel, Belloxa
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Chonnam National University Hospital
Breast Cancer
Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00079170
- Testing
- garlic, docetaxel
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Nausea and Vomiting, Chemotherapy-Induced
The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
The purpose of the study is to evaluate the effect of the study drug (GW679769) on a commonly used chemotherapy drug (docetaxel) which will be given I.V.
- Trial name
- NCT00440128
- Testing
- Docetaxel, Casopitant/Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
The primary objectives of this study are: 1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer (AIPC)…
- Trial name
- NCT00072930
- Testing
- MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid
- Where
- 57 sites in United States, Belgium and 5 more
- Volunteers
- 150 people
- Sponsor
- MedImmune LLC
Metastatic Castration-resistant Prostate Cancer
Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer
Taxotere is the current standard first-line chemotherapy for mCRPC and may be used as second-line therapy in good responders in first-line (Taxotere rechallenge).
- Trial name
- CABA-DOC (NCT02044354)
- Testing
- Taxotere, Jevtana
- Where
- France
- Volunteers
- 195 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Stomach Neoplasms, Esophageal Neoplasms
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Trial name
- NCT00813072
- Testing
- PEP02, irinotecan, docetaxel
- Where
- 22 sites in Bosnia and Herzegovina, Croatia and 4 more
- Volunteers
- 135 people
- Sponsor
- PharmaEngine
Metastatic Castration-Resistant Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT05005728
- Testing
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy
- Where
- 26 sites in United States
- Volunteers
- 72 people
- Sponsor
- Xencor, Inc.
Efficacy, Toxicity
Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy.
- Trial name
- NCT03491371
- Testing
- Methylsulfonic apatinib
- Where
- 2 sites in China
- Volunteers
- 56 people
- Sponsor
- Peking University People's Hospital
Endometrial Cancer, Endometrial Cancer Recurrent
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab…
- Conditions
- Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer
- Trial name
- NCT02922764
- Testing
- RGX-104, Ipilimumab, Docetaxel
- Where
- 21 sites in United States
- Volunteers
- 146 people
- Sponsor
- Inspirna, Inc.
Gastric Cancer
Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
Previously untreated patients with limited metastatic stage (see protocol for details on criteria) will receive 4 cycles of FLOT (5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel).
- Trial name
- FLOT5 (NCT02578368)
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- Germany
- Volunteers
- 183 people
- Sponsor
- Krankenhaus Nordwest
Advanced Non-Hematologic Malignancies
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic…
- Trial name
- NCT01653158
- Testing
- CP-751,871, Docetaxel
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Pfizer
Cancer of the Breast
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer
The study hypothesis is that the addition of Mycograb to docetaxel will improve outcome in advanced carcinoma of the breast.
- Trial name
- NCT00217815
- Testing
- Mycograb, Docetaxel
- Where
- 3 sites in Poland, Serbia
- Volunteers
- 20 people
- Sponsor
- NeuTec Pharma
Non-Small Cell Lung Cancer
Study to Evaluate SID 530 Compared to Taxotere
This is a multi-center, randomized, blinded, two-period, two-sequence, crossover study, with a minimum 3-week washout period between treatments.The study is designed to evaluate the bioequivalence of SID530 to Taxotere.
- Trial name
- NCT00931008
- Testing
- SID530, Taxotere
- Where
- 4 sites in United States, India
- Volunteers
- 42 people
- Sponsor
- SK Chemicals Co., Ltd.
Breast Cancer
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor…
- Trial name
- NCT00703326
- Testing
- ramucirumab (IMC-1121B), docetaxel
- Where
- 232 sites in United States, Australia and 21 more
- Volunteers
- 1,144 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer
Bevacizumab is a monoclonal antibody currently used for the treatment of colorectal cancer. It works by preventing the formation of new blood vessels (angiogenesis).
- Trial name
- NCT01025349
- Testing
- Bevacizumab, docetaxel, cisplatin
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taipei Medical University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.